Sam Fazeli

And I just want to know, you know, I mean, and you've got other companies, you're on the board and shareholders in other companies, you've founded other companies.

If you wanted to also end with telling me what's your genuine excitement about this.

I mean, obviously you have some phenomenal backers, Bob Nelson and the Foresight team and the Arch Ventures team.

So...

I mean, you're in great company with also David Baker.

What is the, I mean, how excited are you about AI in general?

So let's not talk about Xero specifically.

Delivering on its promise, because that is where I think technology sometimes has the risk of promising a lot and not always obviously delivering.

That's wonderful, Mark.

I'm really, really enjoyed the whole conversation, but specifically the last thing I had not heard of eRoom.

No, but just to give you a feel for this, we're modeling.

We were just talking to one of my colleagues the other day.

modeling a new drug, and we were going back and forth about what price to pick.

And so I said, okay, let's just take the average of the past three years of oncology drug launches, what price did they launch at on an annual cost basis, leaving the CAR-Ts aside, because they're one.

Yes.

$315,000.

And you think to yourself, well, we can't keep going like this.

I think pharma needs to, perhaps because their costs.

But maybe if, as you say, we can bring those costs down and the speed to market faster, then maybe they'd be incentivized to bring products to market at a lower price.

I don't want to say more affordable, cheaper.